Scarica l'app Stockscreener
0.3309
12.97%
0.038
Pre-mercato:
.32
-0.0109
-3.29%
Precedente Chiudi:
$0.2929
Aprire:
$0.3
Volume 24 ore:
2.32M
Relative Volume:
0.35
Capitalizzazione di mercato:
$9.42M
Reddito:
$9.37M
Utile/perdita netta:
$-8.45M
Rapporto P/E:
-0.4085
EPS:
-0.81
Flusso di cassa netto:
$-7.27M
1 W Prestazione:
-2.68%
1M Prestazione:
+26.20%
6M Prestazione:
-54.29%
1 anno Prestazione:
-86.38%
Intervallo 1D:
$0.2893
$0.335
Intervallo di 1 settimana:
$0.27
$0.3432
Portata 52W:
$0.1639
$2.9893
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Nome
Bioaffinity Technologies Inc
Settore
Industria
Telefono
210-698-5334
Indirizzo
3300 NACOGDOCHES ROAD, SAN ANTONIO
Confronta BIAF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.3309 | 9.68M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
416.31 | 158.50B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.30 | 143.82B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.57 | 43.48B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.43 | 34.46B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.64 | 28.03B | 15.50B | 1.33B | 2.16B | 7.34 |
Bioaffinity Technologies Inc Borsa (BIAF) Ultime notizie
Before You Invest, Make Sure You Check This BioAffinity Technologies Inc (NASDAQ: BIAF) Analysis - Stocksregister
Why bioAffinity Technologies Inc. Equity Warrant stock attracts strong analyst attentionExpert Backed Predictions - Newser
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic - BioSpace
bioAffinity Technologies Secures Chinese Patent for Lung Cancer Detection - TipRanks
Why bioAffinity Technologies Inc. stock attracts strong analyst attentionFree Best Stocks to Buy Today - Newser
How bioAffinity Technologies Inc. Equity Warrant stock performs during market volatilityFree Short-Term Stock Picks - Newser
How bioAffinity Technologies Inc. stock performs during market volatilityHigh Win Rate Stock Ideas - Newser
What makes bioAffinity Technologies Inc. stock price move sharplyFree Predictions - Newser
What makes bioAffinity Technologies Inc. Equity Warrant stock price move sharplyTargeted 200 Percent Gain - Newser
bioAffinity secures Australian patent for lung cancer test - MSN
bioAffinity Technologies (NASDAQ:BIAFW) Shares Down 10.2% – Should You Sell? - Defense World
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging - Business Wire
The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies - Nasdaq
Top Research Reports for Meta Platforms, ServiceNow & Booking - MSN
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference - The Joplin Globe
Revolutionary siRNA Cancer Therapy Targets Skin Cancer: bioAffinity Secures Key China Patent - Stock Titan
bioAffinity Technologies (NASDAQ:BIAFW) Trading 2.1% Higher – What’s Next? - Defense World
bioAffinity Technologies Stock Price, Quotes and Forecasts | NASDAQ:BIAF - Benzinga
BIAF’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Kalkine : bioAffinity Technologies BIAF Nasdaq Composite - Kalkine Media
bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Growth in Short Interest - Defense World
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board - BioSpace
bioAffinity CEO Joins American Lung Association Texas Leadership Board | BIAFW Stock News - Stock Titan
Gordon Downie Named Chief Medical Officer at bioAffinity Technologies - Medical Product Outsourcing
BIAFbioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - Revista ADVFN
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - mx.advfn.com
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung - Yahoo Finance
Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 58.8% - Defense World
bioAffinity's Game-Changing Lung Cancer Test Gets Nationwide Boost Through Cardinal Health Partnership - Stock Titan
bioAffinity Receives Nasdaq Non-Compliance Notice - TipRanks
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors - Insider Monkey
BioAffinity Technologies Announces New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics - marketscreener.com
BIAF Gains New Patent for Innovative Cancer Treatment Method | B - GuruFocus
Revolutionary Cancer Treatment Patent: bioAffinity's New Therapy Kills Cancer Cells While Sparing Healthy Ones - Stock Titan
bioAffinity Technologies Enters Sales Agreement with WallachBeth - TipRanks
bioAffinity Technologies (NASDAQ:BIAF) Trading Down 3.1% – What’s Next? - Defense World
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline - MSN
bioAffinity Technologies names new chief medical officer By Investing.com - Investing.com South Africa
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer - citybiz
BioAffinity Technologies (BIAF) Appoints Gordon Downie as Chief Medical Officer | BIAF Stock News - GuruFocus
bioAffinity Technologies names new chief medical officer - Investing.com Australia
From Olympic Bronze to Cancer Breakthrough: bioAffinity Names Elite Physician as New CMO - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies Sets 2025 Annual Meeting Date - TipRanks
bioAffinity Technologies Reports Strong Q1 2025 Growth - MSN
Bioaffinity Technologies Inc Azioni (BIAF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):